Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Entreprise · 27/10/20261 min de lecture
Opinion/decision on a Paediatric investigation plan (PIP): Fasenra, Benralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000253868
Traduction automatique locale · Langue originale de la source
Résumé
Opinion/decision on a Paediatric investigation plan (PIP): Fasenra, Benralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorder…
Langue originale de la source: EMA — Paediatric Investigation PlansOuvrir le communiqué original →